Exp Mol Med.  1997 Mar;29(1):53-58.

Retroviral-mediated IL-12 gene therapy for advanced murine tumors

Affiliations
  • 1SEOUL NATL UNIV, INST MOL BIOL & GENET, SEOUL 151742, SOUTH KOREA.
  • 2SEOUL NATL UNIV, DEPT BIOL, SEOUL 151742, SOUTH KOREA.
  • 3UNIV PITTSBURGH, SCH MED, DEPT SURG, PITTSBURGH, PA, 15261.
  • 4UNIV PITTSBURGH, SCH MED, DEPT MOL GENET & BIOCHEM, PITTSBURGH, PA, 15261.
  • 5SAMSUNG MED CTR, DIV HEMATOL ONCOL, SEOUL 135230, SOUTH KOREA.

Abstract

Interleukin 12 (IL-12), a heterodimeric cytokine, promotes an effective antitumor response against tumors of various histological types when delivered systemically as a protein or locally by gene transfer. We investigated parameters that influenced the effectiveness of IL-12 retroviral-mediated gene therapy of cancer in animals using the murine breast cancer line TS/A. Syngeneic fibroblasts (TIB80), stably transduced with a retrovirus expressing murine IL-12, were used for peritumoral injection. Injection of fibroblasts into established tumors resulted in complete regression of tumor in 40 % of animals in a dose dependent manner when treated on day 4, and 20 % when treated on day 8. Significant inhibition of growth of day 21 and day 40 tumors was observed following peritumoral injection of IL-12-expressing fibroblasts in a dose-dependent manner. Delivery of IL-12 by syngeneic fibroblasts at a tumor site is effective in eradicating established, weakly immunogenic TS/A tumors.

Keyword

interleukin-12; cancer; gene therapy

MeSH Terms

Animals
Breast Neoplasms
Fibroblasts
Genetic Therapy*
Interleukin-12*
Retroviridae
Interleukin-12
Full Text Links
  • EMM
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr